TY - JOUR
T1 - A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells
AU - Katayama, Takashi
AU - Kinugawa, Shintaro
AU - Takada, Shingo
AU - Furihata, Takaaki
AU - Fukushima, A.
AU - Yokota, Takashi
AU - Anzai, Toshihisa
AU - Hibino, Mitsue
AU - Harashima, Hideyoshi
AU - Yamada, Yuma
N1 - Funding Information:
We wish to thank Miwako Yamane, Yuki Kimura, Noriko Ikeda, and Chihiro Ogawa for their technical assistance. The flow cytometry analysis in this study was supported by the Platform Project for Supporting in Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) from Japan AMED. We also wish to thank Dr. Milton Feather for his helpful advice in preparing this manuscript.
Funding Information:
This work was supported, in part by, Japan Agency for Medical Research and Development (AMED) , Japan [grant number 17ek0109192h002 to S.K.], a Grant-in-Aid for Scientific Research (B) [grant numbers 26282131 and 17H02094 to Y.Y.] from the Ministry of Education, Culture, Sports, Science and Technology of Japanese Government (MEXT) and the Noguchi-Shitagau Research Grant (to Y.Y.).
Publisher Copyright:
© 2019 Elsevier B.V. and Mitochondria Research Society
PY - 2019/11
Y1 - 2019/11
N2 - Mitochondrial function is reduced in skeletal muscles of many patients with systemic diseases and it is difficult to deliver medicinal substances to mitochondria in such tissue. In this study, we report on attempts to develop liposome-based carriers for mitochondrial delivery using mouse myoblasts (C2C12) by varying the lipid composition of the carriers. We found that a liposome that contains an optimal lipid modified with the KALA peptide (a cellular uptake and mitochondrial targeting device) was the most effective nanocarrier for achieving mitochondrial delivery in C2C12 cells. We also report on successful mitochondrial transgene expression using the carriers encapsulating a mitochondrial DNA vector as we previously reported.
AB - Mitochondrial function is reduced in skeletal muscles of many patients with systemic diseases and it is difficult to deliver medicinal substances to mitochondria in such tissue. In this study, we report on attempts to develop liposome-based carriers for mitochondrial delivery using mouse myoblasts (C2C12) by varying the lipid composition of the carriers. We found that a liposome that contains an optimal lipid modified with the KALA peptide (a cellular uptake and mitochondrial targeting device) was the most effective nanocarrier for achieving mitochondrial delivery in C2C12 cells. We also report on successful mitochondrial transgene expression using the carriers encapsulating a mitochondrial DNA vector as we previously reported.
UR - http://www.scopus.com/inward/record.url?scp=85069642020&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069642020&partnerID=8YFLogxK
U2 - 10.1016/j.mito.2019.07.005
DO - 10.1016/j.mito.2019.07.005
M3 - Article
C2 - 31326598
AN - SCOPUS:85069642020
SN - 1567-7249
VL - 49
SP - 66
EP - 72
JO - Mitochondrion
JF - Mitochondrion
ER -